Metformin use and cardiovascular events in patients with type 2 diabetes and chronic kidney disease
Article 2019 en
Authors
DC
David M. Charytan
SS
Scott D. Solomon
PI
Peter Ivanovich
Abstract
1 min read
Metformin may be safer for use in CKD than previously considered and may lower the risk of death and cardiovascular events in individuals with stage 3 CKD.
Dick de Zeeuw, Tadao Akizawa, Paul Audhya, George L. Bakris, Melanie Chin, Heidi Christ‐Schmidt, Angie Goldsberry, Mark T. Houser, Melissa Krauth, Hiddo J.L. Heerspink, John J.V. McMurray, Colin J. Meyer, Hans‐Henrik Parving, Giuseppe Remuzzi, Robert D. Toto, Nosratola D. Vaziri, Christoph Wanner, Janet Wittes, Danielle Wrolstad, Glenn M. Chertow
Finnian R. Mc Causland, Brian Claggett, Petr Jarolı́m, Martina M. McGrath, Emmanuel A. Burdmann, Kai-Uwe Eckardt, Andrew S. Levey, John J.V. McMurray, Giuseppe Remuzzi, Ajay Singh, Scott D. Solomon, Robert D. Toto, Marc A. Pfeffer
Finnian R. Mc Causland, B Claggett, Petr Jarolı́m, Martina M. McGrath, Emmanuel A. Burdmann, Andrew S. Levey, John J.V. McMurray, Giuseppe Remuzzi, Scott D Solomon, Marc A. Pfeffer
Akshay S. Desai, Henry Krum, Changhong Yu, Scott M. Wasserman, Eduard Apetrei, Vijay Chopra, Mareev VIu, Aldo Maggioni, John J.V. McMurray, Marc A. Pfeffer, Karl Swedberg, James B. Young
.webp){kind=small}
Discussion(0)
No comments yet. Be the first to comment.